fr en es de it pt nl

Reagents and instruments for immunology, cell biology and molecular biology.

Search result : 14 product found

Refine your search :

RUOCE / IVD

Unconjugated 9

Inhibitor/Antagonist/Agonist 14

APPLY FILTERS
REINITIALIZE

Cat#

Description

Cond.

Price Bef. VAT

orb1910676-250mg

COH1 is a ribonucleotide reductase (RR) inhibitor. COH1 can be used in research into cancer, mitochondrial diseases, and neurodegenerative diseases. [[20217-22-5]]

250mg

orb1910676-100mg

COH1 is a ribonucleotide reductase (RR) inhibitor. COH1 can be used in research into cancer, mitochondrial diseases, and neurodegenerative diseases. [[20217-22-5]]

100mg

orb1910676-1g

COH1 is a ribonucleotide reductase (RR) inhibitor. COH1 can be used in research into cancer, mitochondrial diseases, and neurodegenerative diseases. [[20217-22-5]]

1g

orb1910646-1g

ABX-002 is a novel CNS-penetrant TR-B agonist prodrug with potential for treatment of demyelinating disorders as well as other neuroinflammatory and/or neurodegenerative diseases.

1g

orb1910646-250mg

ABX-002 is a novel CNS-penetrant TR-B agonist prodrug with potential for treatment of demyelinating disorders as well as other neuroinflammatory and/or neurodegenerative diseases.

250mg

orb1910646-100mg

ABX-002 is a novel CNS-penetrant TR-B agonist prodrug with potential for treatment of demyelinating disorders as well as other neuroinflammatory and/or neurodegenerative diseases.

100mg

orb1910497-1g

Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy. [[60477-34-1]]

1g

orb1910497-100mg

Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy. [[60477-34-1]]

100mg

orb1910497-250mg

Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy. [[60477-34-1]]

250mg

HY-L086-30ul

Neurodegenerative Disease-related Compound Library

30ul

HY-L086-100ul

Neurodegenerative Disease-related Compound Library

100ul

HY-L086-250ul

Neurodegenerative Disease-related Compound Library

250ul

HY-L086-50ul

Neurodegenerative Disease-related Compound Library

50ul

HY-L086-2x100ul

Neurodegenerative Disease-related Compound Library

2x100ul

‹

›